The Sevoflurane study, understanding the effects of Sevoflurane to improve safety and outcome of cardiac surgery - Sevo-study

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-012372-27-NL

Enrollment

Registered

2009-07-10

Start date

2009-09-17

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial ischemia reperfusion injury during cardiac surgery MedDRA version: 9.1 Level: LLT Classification code 10017501 Term: Functional disturbances following cardiac surgery

Interventions

Trade Name: Sevoflurane Product Name: Sevoflurane Pharmaceutical Form: Inhalation gas INN or Proposed INN: SEVOFLURANE CAS Number: 28523866 Concentration unit: % (V/V) percent volume/volume Concentrat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients without heart failure (EF =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Acceptation for minimal invasive mitral valve surgery, inability to sign informed consent, less than 18 years old, emergency operations

Design outcomes

Primary

Measure	Time frame
Main Objective: Understanding the effects of Sevoflurane on ischemia reperfusion injury of the myocardium to improve safety and outcome of cardiac surgery;Secondary Objective: ;Primary end point(s): Inflammatory biomarkers	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026